Material and Methods:
We generated FancA overexpressing human oral keratinocytes (OKF6/FancA) and analyzed several endpoints upon irradiation. To identify signaling pathways involved in FancA-mediated resistance, global transcriptome analyses were performed after irradiation with 4 Gy or shamirradiation followed by pathway enrichment analysis and reconstruction of function interaction networks. The clinical relevance of the cytogenetic marker 16q23-24, the FancA gene and our in vitro results was analyzed in data of 113 radiotherapy-treated patients from The Cancer Genome Atlas (TCGA) HNSCC cohort (Nature, 2015) .
Results:
Overexpression of FancA resulted in enhanced survival after in vitro irradiation. Moreover, FancA overexpressing cells demonstrated accelerated DNA damage repair mechanisms paralleled by increased repair fidelity: enhanced p53 and p21 response, accelerated kinetics in the disappearance of γ-H2AX DNA damage repair foci, faster pATM translocation, reduced accumulation of chromosomal translocations, but no increase in FancD2 monoubiquitinylation. Global mRNA expression analyses identified interferon signaling as a major candidate pathway, which was affected by FancA overexpression. Functional interaction networks of genes deregulated upon irradiation pointed to pathways exclusively involved in FancA-mediated radioresistance including the senescence-associated secretory phenotype (SASP) . Increased levels of basal and irradiationinduced cellular senescence accompanied by enforced SASP formation further support their potential involvement in FancA-mediated radiation resistance. The clinical relevance of our findings was validated in the data of 113 radiotherapytreated patients of the TCGA HNSCC cohort demonstrating the association of chromosomal gains on 16q24.3 with increased FancA mRNA expression levels and impaired overall survival. Furthermore, the translation of our in vitro model derived results into the HNSCC patient specimens revealed similar gene expression changes linked to FancA overexpression.
Conclusion:
Our data suggest an important role for FancA in cellular mechanisms of radioresistance in HNSCC. Purpose or Objective: The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival in bladder cancer patients enrolled in the BCON phase III clinical trial. We investigated whether the expression of miR-210 in the BCON patient samples reflects hypoxia and predicts benefit from hypoxiamodification.
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Material and Methods:
The retrospective study involved 183 T1-T4b patients: 86 received RT+CON and 97 received RT alone. Formalin-fixed samples taken prior to radiotherapy were available and RNA extracted. Customised TaqMan plates were used to assess miR-210 expression using quantitative real-time PCR. Patients were classified as low miR-210 (<median expression) or high miR-210 (≥ median). Data on other hypoxia biomarkers were available for comparison.
Results:
Patients with high miR-210 had a trend towards improved five-year OS with RT+CON (53.2%) compared with RT alone (37.8%; HR 1.68, 95% CI 0.95-2.95, P=0.08). No benefit was seen with low miR-210 (HR 1.02, 95% CI 0.58-1.79, P=0.97). High expression of miR-210 was also associated with high HIF-1α protein (P=0.0008), CA9 protein (P=0.004), Glut-1 protein (P=0.02), expression of a 26-gene hypoxia signature (P=0.01), tumour necrosis (P=0.04) and concurrent pTis (P=0.03).
Conclusion:
High miR-210 expression may reflect tumour hypoxia and should be investigated further as a potential biomarker to identify bladder cancer patients who would benefit from hypoxia-modifying therapies. The DNA cytosine deaminase APOBEC3 proteins catalyze deamination of cytidines in single-stranded DNA, providing innate protection against retroviral replication. Recent studies have implicated APOBEC3B as a major source of mutation in breast cancer, suggesting a role for these enzymes in tumor initiation and/or progression. APOBEC3B expression levels were earlier found to correlate with poor outcomes for patients with estrogen receptor positive breast cancer, especially after Tamoxifen. Given its role in mutagenesis, we set out to assess whether APOBEC3B associates with radiosensitivity in breast cancer.
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Material and Methods:
MCF7 breast cancer cells were cultured radioresistant by daily 2 Gy treatments or tamoxifen-resistant by continuous culturing in up to 10 uM 4-OH-tamoxifen. The effect of irradiation on expression of APOBECs was assessed by RNAseq and qPCR in radiosensitive and radioresistant MCF7, and by qPCR in radioresistant MDA-MB231 cells. Furthermore, we studied a retrospective cohort of 535 non-systemically treated breast cancer patients. The predictive power of APOBEC3B was assessed in patients that did or did not receive radiotherapy as part of their primary therapy. Next, we suppressed endogenous APOBEC3B in MCF-7L with shRNA, or overexpressed either wt APOBEC3B, or a catalytically dead mutant APOBEC3B.
Results: Radioresistant breast cancer cells had increased baseline APOBEC3B mRNA levels (and not of any of the other APOBEC proteins), and irradiation induced an increase in APOBEC3B expression in both MCF7 and MDA-MB231 cells. In the breast cancer patient cohort we found a strong, statistically significant, independent interaction between APOBEC3B expression and radiotherapy. APOBEC3B predicted a poor prognosis only in those patients that received radiotherapy as part of their primary treatment, also when this analysis was restricted to patients that received a mastectomy ( figure) . This suggests that APOBEC3B influences radiosensitivity, and does not merely predict efficacy of surgery (as radiotherapy is generally given to lumpectomy patients). The effect of APOBEC3B knockdown and overexpression on radiosensitivity is currently being assessed using colony-forming assays and will be presented.
Conclusion:
Our data suggest that the anti-viral APOBEC3B enzyme influences radiosensitivity in breast cancer, and might be a potential target for radiosensitization. 
Material and Methods:
We retrospectively reviewed 17 liver transplant candidates from December 2008 to December 2013 at a single institution with discrete HCC lesions were treated with SBRT for evaluation of local control (LC); other methods of bridging patients to transplant were also available. Peripheral SBRT dose was either 50 Gy in 5 fractions or 45 Gy in 3 fractions with 2 fractions weekly. The records of transplant patients who underwent SBRT for single or multiple hepatomas were reviewed for maximum tumor dimension (MTD) at time of simulation, last imaging before transplant, and gross pathology following transplant. Radiographic LC of the treated lesion was defined as stable or decreasing enhancement on imaging with either triplephase CT Liver or MRI Liver prior to transplant as demonstrated in Figure 1 ; this was recorded one month subsequent to treatment and just before the transplant. Pathologic Control (PC) was defined as stable to decreased size in MTD and/or no viable tumor present.
Results:
Twelve patients have successfully been transplanted. All patients were male with a median age of 57 years. Of the 12 patients transplanted, there were 17 lesions treated. Median MTD at time of radiation was 3.6 cm (1.1cm -6.1 cm). Median time to transplant from radiation treatment for 12 patients was 9 months (2mo-18mo). Table 1 summarizes tumor and treatment characteristics. Eight lesions (47%) had no evidence of viable tumor on pathology. Radiographic LC and PC was achieved in all 17 lesions. At a median follow-up of 53 months, disease free and overall survival were 100% with no evidence of disease (NED). Of the remaining 5 candidates, 3 patients awaiting transplant had one lesion, 1 had two lesions, and 1 had three lesions treated via SBRT. No patient experienced significant decrement in liver function nor indication of radiation induced liver disease. One patient experienced Grade 1 abdominal pain and three patients experienced Grade 1 nausea.
Conclusion:
SBRT for HCC lesions in transplant candidates is an effective means of LC with successful bridging to transplant. Radiologic assessment subsequent to SBRT correlated with pathologic findings after transplant. These promising results suggest a broader role for SBRT in management of limited volume HCC.
